Target Name: UBBP1
NCBI ID: G7315
Other Name(s): ubiquitin B pseudogene 1 | Ubiquitin B pseudogene 1

Studies Suggest UBBP1 May Be A Potential Drug Target Or Biomarker for Various Diseases

Ubiquitin B pseudogene 1 (UBBP1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. UBBP1 is a protein that is involved in the ubiquitin system, which is a protein degradation pathway that plays a crucial role in maintaining cellular homeostasis and has been implicated in many diseases.

The ubiquitin system is a complex protein degradation pathway that involves a variety of proteins, including ubiquitin, which is a protein that is involved in the degradation of other proteins, and ubiquitin-like modifiers, which are proteins that bind to ubiquitin and enhance its activity. UBBP1 is a gene that encodes a protein that is similar to ubiquitin but has been rearranged to have a different sequence.

Studies have suggested that UBBP1 may be involved in a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, studies have found that UBBP1 is often expressed at higher levels in tissues that are affected by cancer, and that it may be a potential biomarker for cancer. Additionally, UBBP1 has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Another study found that UBBP1 was expressed at higher levels in the brains of individuals with multiple sclerosis, a neurodegenerative disorder that causes muscle weakness and stiffness. Additionally, UBBP1 has been shown to be involved in the development and progression of autoimmune diseases, including rheumatoid arthritis and lupus.

While more research is needed, UBBP1 is an intriguing protein that may be a drug target or biomarker for a variety of diseases. If further research confirms these findings, UBBP1 may become a valuable tool for the development of new treatments for these diseases.

Protein Name: Ubiquitin B Pseudogene 1

More Common Targets

UBBP2 | UBBP4 | UBC | UBD | UBDP1 | UBE2A | UBE2B | UBE2C | UBE2CP3 | UBE2CP4 | UBE2D1 | UBE2D2 | UBE2D3 | UBE2D3P1 | UBE2D4 | UBE2DNL | UBE2E1 | UBE2E2 | UBE2E3 | UBE2F | UBE2F-SCLY | UBE2FP1 | UBE2G1 | UBE2G2 | UBE2H | UBE2HP1 | UBE2I | UBE2J1 | UBE2J2 | UBE2K | UBE2L1 | UBE2L3 | UBE2L6 | UBE2M | UBE2MP1 | UBE2N | UBE2NL | UBE2O | UBE2Q1 | UBE2Q2 | UBE2Q2P1 | UBE2Q2P11 | UBE2Q2P13 | UBE2Q2P16 | UBE2Q2P2 | UBE2QL1 | UBE2R2 | UBE2R2-AS1 | UBE2S | UBE2T | UBE2U | UBE2V1 | UBE2V1P2 | UBE2V1P9 | UBE2V2 | UBE2V2P1 | UBE2W | UBE2Z | UBE3A | UBE3B | UBE3C | UBE3D | UBE4A | UBE4B | UBFD1 | UBIAD1 | Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 | Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex | UBL3 | UBL4A | UBL4B | UBL5 | UBL5P3 | UBL7 | UBL7-DT | UBLCP1 | UBN1 | UBN2 | UBOX5 | UBOX5-AS1 | UBP1 | UBQLN1 | UBQLN1-AS1 | UBQLN2 | UBQLN3 | UBQLN4 | UBQLNL | UBR1 | UBR2 | UBR3 | UBR4 | UBR5 | UBR5-DT | UBR7 | UBTD1 | UBTD2 | UBTF | UBTFL1 | UBTFL2 | UBTFL6